Intervention/Structural ACS Cardiac Surgery

Journal Club - January 20, 2022DEFINE PCI Trial 1 Year Outcomes Madeleine Barker presented the DEFINE PCI Trial 1 Year Outcomes. The DEFINE PCI trial (Physiologic Assessment of Coronary Stenosis Following PCI) was a

Journal Club - January 13, 2022AVATAR Trial Isabel Kim presented the AVATAR Trial, which is an investigator-initiated international prospective randomized controlled trial that evaluated the safety and efficacy of early SAVR compared to conservative treatment

Journal Club - December 2, 2021CTCR-MVS Trial Dr. Nav Malhi presented the CTCR-MVS Trial, which is a randomized, surgical trial comparing mitral valve surgery with or without tricuspid annuloplasty (TA) among patients who were undergoing mitral-valve

Journal Club - October 28, 2021IAMI Trial Dr. Kurt Hoskin presented the IAMI Trial, which is an investigator-initiated, randomized, double-blind trial to compare inactivated influenza vaccine with saline placebo administered

Journal Club - October 20, 2021TAVR Explant: An Emerging Necessity in the Lifetime Management of Aortic Valve Disease Dr. Gilbert Tang, Surgical Director of the Structural Heart Program at the

Journal Club - October 14, 2021TOMAHAWK Trial Dr. Curtis Williams presented the TOMAHAWK Trial, which is a multicenter, randomized clinical trial comparing immediate coronary angiography to initial intensive care assessment with delayed or selective angiography among

Journal Club - August 12, 2021TTM2 Trial Dr. Ian Pitcher presented the TTM2 Trial, which is an open-label trial with blinded assessment of outcomes comparing targeted hypothermia at 33°C, followed

Journal Club - May 6, 2021RHAPSODY Trial Dr. Nav Malhi presented the RHAPSODY Trial, which is a phase 3, multicenter, double-blind, event-driven, randomized-withdrawal trial of rilonacept in patients with acute

Journal Club - April 15, 2021Outcomes 2 Years After Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk Dr. Madeleine Barker presented the Two Years Outcomes of PARTNER 3, which is a randomized